SCHEMBL12420751

SCHEMBL12420751

O=C(O)c1ccnc(OCCc2cccc(F)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 6/20 0.57
KDM5B Q9UGL1 6/20 0.57
KDM4C Q9H3R0 5/20 0.57
NR4A2 P43354 3/20 0.52
NR3C2 P08235 1/20 0.46
CSNK2A2 P19784 2/20 0.44
CSNK2A1 P68400 2/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
PPARA Q07869 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.43
LOXL2 Q9Y4K0 1/20 0.43
ALKBH1 Q13686 1/20 0.42
KDM2B Q8NHM5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12420736 0.86 KDM5A (0.52) KDM5AKDM5BKDM4CNR4A2LOXL2
SCHEMBL958328 0.80 GPR52 (0.57) KDM5AKDM5BKDM4CNR4A2CYP4F2
SCHEMBL12420743 0.78 KDM5A (0.55) KDM5AKDM5BKDM4CNR3C2CYP4F2
SCHEMBL2196514 0.76 KDM5A (0.77) KDM5AKDM5BKDM4CNR4A2NR3C2
SCHEMBL837794 0.75 NR4A2 (0.58) KDM5AKDM5BKDM4CNR4A2MRGPRX4
SCHEMBL12420867 0.74 NR4A2 (0.50) KDM5AKDM5BKDM4CNR4A2MRGPRX4
SCHEMBL2546283 0.74 KDM4C (0.50) KDM5AKDM5BKDM4CLOXL2
SCHEMBL25049489 0.73 KDM4C (0.57) KDM5AKDM5BKDM4C
SCHEMBL2195411 0.73 KDM4C (0.55) KDM5AKDM5BKDM4CNR4A2ALKBH1
SCHEMBL12420863 0.72 NR3C2 (0.46) KDM5AKDM5BKDM4CNR3C2PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172230-A1 UREA COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-07-14 US disclosed
US-20110172230-A1 UREA COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172230-A1 UREA COMPOUND OR SALT THEREOF FAAH, FAAH2, UTS2R KDM5A 301/4885KDM5B 304/4885KDM4C 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.